Rolf C, von Eckardstein S, Koken U, Nieschlag E
Institute of Reproductive Medicine of the University, Domagkstrasse 11, D-48129 Münster, Germany.
Eur J Endocrinol. 2002 Apr;146(4):505-11. doi: 10.1530/eje.0.1460505.
In healthy men, body weight and total fat content increase with advancing age, while serum testosterone levels decrease. In order to elucidate whether a causal relationship between these phenomena exists, we investigated the influence of testosterone or human chorionic gonadotrophin substitution on body mass index (BMI), total fat mass and serum leptin in testosterone-treated and untreated hypogonadal patients in comparison with ageing eugonadal men.
In a cross-sectional study, the inter-relationships of body weight, total fat mass, serum sex hormones and leptin were analysed in untreated hypogonadal men (n=24; age 19-65 years), treated hypogonadal men (n=61; age 20-67 years) and healthy eugonadal men (n=60; age 24-78 years). Total fat mass was assessed by bioimpedance measurement. Univariate and multiple linear regression analysis was used to detect possible differences.
In eugonadal men, serum testosterone levels decreased with advancing age (correlation coefficients: r=-0.71; P<0.0001), while BMI (r=0.39; P=0.002), total fat content (r=0.51; P<0.0001) and leptin (r=0.48; P<0.0001) increased significantly. In untreated hypogonadal patients, an increase in BMI (r=0.50; P=0.013) and total fat mass (r=0.41; P=0.044) was also observed with advancing age. However, in substituted hypogonadal patients, no age-dependent change in BMI (r=0.067; P=0.606), body fat content (r=-0.083; P=0.522), serum testosterone (r=-0,071; P=0.59) or serum leptin (r=-0.23; P=0.176) was found.
Since testosterone-substituted older hypogonadal men show BMI and fat mass similar to those of younger eugonadal men and since non-treated hypogonadal men are similar to normal ageing men, testosterone appears to be an important factor contributing to these changes. Thus ageing men should benefit from testosterone substitution as far as body composition is concerned.
在健康男性中，体重和总脂肪含量会随着年龄的增长而增加，而血清睾酮水平则会下降。为了阐明这些现象之间是否存在因果关系，我们研究了睾酮或人绒毛膜促性腺激素替代疗法对接受睾酮治疗和未接受治疗的性腺功能减退患者的体重指数（BMI）、总脂肪量和血清瘦素的影响，并与年龄增长的性腺功能正常男性进行了比较。
在一项横断面研究中，分析了未接受治疗的性腺功能减退男性（n = 24；年龄19 - 65岁）、接受治疗的性腺功能减退男性（n = 61；年龄20 - 67岁）和健康性腺功能正常男性（n = 60；年龄24 - 78岁）的体重、总脂肪量、血清性激素和瘦素之间的相互关系。通过生物电阻抗测量评估总脂肪量。采用单因素和多因素线性回归分析来检测可能存在的差异。
在性腺功能正常的男性中，血清睾酮水平随着年龄的增长而下降（相关系数：r = -0.71；P < 0.0001），而BMI（r = 0.39；P = 0.002）、总脂肪含量（r = 0.51；P < 0.0001）和瘦素（r = 0.48；P < 0.0001）则显著增加。在未接受治疗的性腺功能减退患者中，随着年龄的增长，BMI（r = 0.50；P = 0.013）和总脂肪量（r = 0.41；P = 0.044）也有所增加。然而，在接受替代治疗的性腺功能减退患者中，未发现BMI（r = 0.067；P = 0.606）、体脂含量（r = -0.083；P = 0.522）、血清睾酮（r = -0.071；P = 0.59）或血清瘦素（r = -0.23；P = 0.176）随年龄变化。
由于接受睾酮替代治疗的老年性腺功能减退男性的BMI和脂肪量与年轻性腺功能正常男性相似，且未接受治疗的性腺功能减退男性与正常衰老男性相似，因此睾酮似乎是导致这些变化的一个重要因素。因此，就身体成分而言，老年男性可能会从睾酮替代治疗中受益。
